Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

WuXi Vaccines Signs $3 Billion, 20-Year Agreement to Manufacture Vaccine

publication date: Feb 21, 2020

WuXi Vaccines finalized a $3 billion 20-year agreement with an unspecified "global vaccine leader" to manufacture a vaccine for the company. Last year, WuXi Vaccines, a joint venture comprised of WuXi Biologics and Shanghai Hile Bio-technology, began building a $240 million production facility in Ireland that will provide worldwide supplies of the vaccine. The facility is next to a major facility under construction for WuXi Biologics. WuXi and the unnamed vaccine maker expect the vaccine to produce $3 billion in revenues over 20 years. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020